Form 8-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 9, 2006
 
King Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 
Tennessee
(State or other jurisdiction
of incorporation)
 
001-15875
(Commission
File Number)
 
54-1684963
(IRS Employer
Identification Number)

501 Fifth Street, Bristol, Tennessee
(Address of principal executive offices)
 
37620
(Zip Code)
 
Registrant’s telephone number, including area code: 423-989-8000
 
Not Applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
Item 2.02 Results of Operations and Financial Condition.
 
On August 9, 2006, King Pharmaceuticals, Inc. announced its consolidated financial results for the three and six months ended June 30, 2006. A copy of the press release issued in connection with the announcement is being furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K.
 
 
Item 9.01 Financial Statements and Exhibits.
 
(d)  
Exhibits:
 
Exhibit
Number
Description of Exhibit
 
99.1
 
Press release issued by King Pharmaceuticals, Inc. dated August 9, 2006.

 
The press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
 
 

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

Date: August 9, 2006
KING PHARMACEUTICALS, INC.
 
By:
/s/ Brian A. Markison
Brian A. Markison
President and Chief Executive Officer